64080-16-6

Upstream product

• 645-56-7 4-n-Propylphenol 

Downstream Products

• 1391839-23-8 4-n-propyl-2-((trimethylsilyl)ethynyl)phenyl acetate 
• 1389251-35-7 2-ethynyl-4-n-propylphenol 
• 1375102-97-8 2-ethynyl-4-n-propylphenyl acetate 
• 1375103-03-9 2-(1-allyl-1H-1,2,3-triazol-4-yl)-4-n-propylphenyl acetate 
• 1375102-98-9 2-(1-allyl-1H-1,2,3-triazol-4-yl)-4-n-propylphenol 
• 1375102-99-0 2-(1-(cyclobutylmethyl)-1H-1,2,3-triazol-4-yl)-4-n-propylphenol 
• 1375103-04-0 C₁₈H₂₃N₃O₂ 
• 1375102-96-7 2-bromo-4-n-propylphenyl acetate 
• 1413440-39-7 2-hydroxy-5-propylphenylboronic acid 
• 20601-85-8 tetrahydromagnolol 
• 101538-30-1 2-bromo-1-methoxy-4-propylbenzene 

Relevant academic research and scientific papers

Ether compound and pharmaceutical application thereof in prevention and treatment of diabetes and metabolic syndrome

The invention relates to an ether compound and a pharmaceutical application thereof in prevention and treatment of diabetes and metabolic syndrome. Specifically, the invention provides a compound as shown in a formula (I), an isomer, a raceme, a prodrug, a solvate, a deuterated substance or a pharmaceutically acceptable salt thereof, and Ar1, Ar2, X, Y and R are defined in the specification.

Palladium-catalyzed paraformaldehyde insertion: A three-component synthesis of benzofurans

An efficient procedure for 2-aroylbenzofuran preparation from 2-bromophenols, phenacyl bromides and paraformaldehyde is described. The cheap and stable paraformaldehyde served as the carbon source via an in situ formylation reaction.

Structural analogues of the natural products magnolol and honokiol as potent allosteric potentiators of GABAA receptors

Biphenylic compounds related to the natural products magnolol and 4′-O-methylhonokiol were synthesized, evaluated and optimized as positive allosteric modulators (PAMs) of GABAA receptors. The most efficacious compounds were the magnolol analog 5-ethyl-5′-hexylbiphenyl-2,2′-diol (45) and the honokiol analogs 4′-methoxy-5-propylbiphenyl-2-ol (61), 5-butyl-4′-methoxybiphenyl-2-ol (62) and 5-hexyl-4′-methoxybiphenyl-2-ol (64), which showed a most powerful potentiation of GABA-induced currents (up to 20-fold at a GABA concentration of 3 μM). They were found not to interfere with the allosteric sites occupied by known allosteric modulators, such as benzodiazepines and N-arachidonoylglycerol. These new PAMs will be useful as pharmacological tools and may have therapeutic potential for mono-therapy, or in combination, for example, with GABAA receptor agonists.

Magnolia extract, magnolol, and metabolites: Activation of cannabinoid CB2 receptors and blockade of the related GPR55

The bark of Magnolia officinalis is used in Asian traditional medicine for the treatment of anxiety, sleeping disorders, and allergic diseases. We found that the extract and its main bioactive constituents, magnolol and honokiol, can activate cannabinoid

Design and synthesis of 4-O-methylhonokiol analogs as inhibitors of cyclooxygenase-2 (COX-2) and PGF1 production

A series of novel 4-O-methylhonokiol analogs were synthesized in light of revealing structure-activity relationship for inhibitory effect of COX-2 enzyme. The key strategy of the molecular design was oriented towards modification of the potential metabolic soft spots (e.g., phenol and olefin) or by altering the polar surface area via incorporating heterocycles such as isoxazole and triazole. Most of all exhibited the inhibitory effects on COX-2 and PGF 1 production but not macrophage NO production. Especially, aryl carbamates 10 and 11 exhibited more potent inhibitory activity against COX-2 and PGF1 production.